SMS Pharmaceuticals Limited share price
NSE: SMSPHARMA · ISIN INE812G01025
Key numbers
- Market cap
- ₹ 4,448 Cr
- Current price
- ₹ 475.00
- 52-week high / low
- ₹ 494 / 242
- Stock P/E
- 43.7
- Book value
- ₹ 83.9
- Dividend yield
- 0.08%
- ROCE
- 13.2%
- ROE
- 14.3%
- Debt to equity
- 0.46
- Sales growth (3 yrs)
- 19.3%
- Profit growth (3 yrs)
- -
- 1-year return
- 65.7%
About SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 196 | 242 | 210 | 238 | 207 |
| Operating profit | 38 | 48 | 44 | 40 | 41 |
| Net profit | 20 | 25 | 23 | 33 | 21 |
| EPS (₹) | 2.31 | 2.84 | 2.59 | 3.58 | 2.23 |
Investor presentation summary (2026-08-01)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Revenue up 6% YoY, driven by diversified growth across
- EBITDA margin sustained at ~20%; PAT up 8% YoY
Guidance & outlook
- Completed 4 DMF/CEP filings; on track to meet FY27
- expected to be completed by FY27
Growth & demand
- future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows,
- development pipeline of niche and high-value APIs and
Margins & costs
- Gross margin remained above 45%, reflecting structural
- Operating leverage drives cost efficiency, enabling competitive pricing and faster market share gains
Capex & expansion
- ₹280 crore capex programme progressing as planned;
- Successful expansion into
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.